Literature DB >> 22972920

B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells.

Jun Sik Lee1, Lisa Scandiuzzi, Anjana Ray, Joyce Wei, Kimberly A Hofmeyer, Yael M Abadi, P'ng Loke, Juan Lin, Jianda Yuan, David V Serreze, James P Allison, Xingxing Zang.   

Abstract

B7x (B7-H4 or B7S1) is the seventh member of the B7 family, and its in vivo function remains largely unknown. Despite new genetic data linking the B7x gene with autoimmune diseases, how exactly it contributes to peripheral tolerance and autoimmunity is unclear. In this study, we showed that B7x protein was not detected on APCs or T cells in both human and mice, which is unique in the B7 family. Because B7x protein is expressed in some peripheral cells such as pancreatic β cells, we used a CD8 T cell-mediated diabetes model (AI4αβ) in which CD8 T cells recognize an endogenous self-Ag, and found that mice lacking B7x developed more severe diabetes than control AI4αβ mice. Conversely, mice overexpressing B7x in the β cells (Rip-B7xAI4αβ) were diabetes free. Furthermore, adoptive transfer of effector AI4αβ CD8 T cells induced diabetes in control mice, but not in Rip-B7xAI4αβ mice. Mechanistic studies revealed that pathogenic effector CD8 T cells were capable of migrating to the pancreas but failed to robustly destroy tissue when encountering local B7x in Rip-B7xAI4αβ mice. Although AI4αβ CD8 T cells in Rip-B7xAI4αβ and AI4αβ mice showed similar cytotoxic function, cell death, and global gene expression profiles, these cells had greater proliferation in AI4αβ mice than in RIP-B7xAI4αβ mice. These results suggest that B7x in nonlymphoid organs prevents peripheral autoimmunity partially through inhibiting proliferation of tissue-specific CD8 T cells, and that local overexpression of B7x on pancreatic β cells is sufficient to abolish CD8 T cell-induced diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972920      PMCID: PMC3466330          DOI: 10.4049/jimmunol.1201241

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

Review 1.  Etiology of type 1 diabetes.

Authors:  John A Todd
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

2.  Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.

Authors:  Xingxing Zang; Peggy S Sullivan; Robert A Soslow; Rebecca Waitz; Victor E Reuter; Andrew Wilton; Howard T Thaler; Manonmani Arul; Susan F Slovin; Joyce Wei; David R Spriggs; Jakob Dupont; James P Allison
Journal:  Mod Pathol       Date:  2010-05-21       Impact factor: 7.842

Review 3.  The PD-1 pathway in tolerance and autoimmunity.

Authors:  Loise M Francisco; Peter T Sage; Arlene H Sharpe
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

Review 4.  The role of perforin and granzymes in diabetes.

Authors:  H E Thomas; J A Trapani; T W H Kay
Journal:  Cell Death Differ       Date:  2009-11-20       Impact factor: 15.828

5.  Interaction of T-cell and antigen presenting cell co-stimulatory genes in childhood IgE.

Authors:  R W B Bottema; D S Postma; N E Reijmerink; C Thijs; F F Stelma; H A Smit; C P van Schayck; B Brunekreef; G H Koppelman; M Kerkhof
Journal:  Eur Respir J       Date:  2009-07-02       Impact factor: 16.671

6.  The molecular signature of CD8+ T cells undergoing deletional tolerance.

Authors:  Ian A Parish; Sudha Rao; Gordon K Smyth; Torsten Juelich; Gareth S Denyer; Gayle M Davey; Andreas Strasser; William R Heath
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

7.  B7-H4 transfection prolongs beta-cell graft survival.

Authors:  Chun-Lei Yuan; Jun-Fa Xu; Jing Tong; Heng Yang; Feng-Rong He; Quan Gong; Ping Xiong; Lihua Duan; Min Fang; Zheng Tan; Yong Xu; Yi-Fa Chen; Fang Zheng; Fei-Li Gong
Journal:  Transpl Immunol       Date:  2009-04-08       Impact factor: 1.708

Review 8.  How interferon-gamma keeps autoimmune diseases in check.

Authors:  Hilde Kelchtermans; Alfons Billiau; Patrick Matthys
Journal:  Trends Immunol       Date:  2008-09-03       Impact factor: 16.687

9.  Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses.

Authors:  Yosuke Kamimura; Hiroko Kobori; Jinhua Piao; Masaaki Hashiguchi; Koichiro Matsumoto; Sachiko Hirose; Miyuki Azuma
Journal:  Biochem Biophys Res Commun       Date:  2009-08-31       Impact factor: 3.575

10.  Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis.

Authors:  Anne Hinks; Anne Barton; Neil Shephard; Steve Eyre; John Bowes; Michele Cargill; Eric Wang; Xiayi Ke; Giulia C Kennedy; Sally John; Jane Worthington; Wendy Thomson
Journal:  Arthritis Rheum       Date:  2009-01
View more
  22 in total

1.  Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Authors:  Jenessa B Smith; Evripidis Lanitis; Denarda Dangaj; Elizabeth Buza; Mathilde Poussin; Caitlin Stashwick; Nathalie Scholler; Daniel J Powell
Journal:  Mol Ther       Date:  2016-07-21       Impact factor: 11.454

2.  Host b7x promotes pulmonary metastasis of breast cancer.

Authors:  Yael M Abadi; Hyungjun Jeon; Kim C Ohaegbulam; Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Jun Sik Lee; Anjana Ray; Claudia Gravekamp; Xingxing Zang
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

3.  Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Authors:  Asim Saha; Patricia A Taylor; Christopher J Lees; Angela Panoskaltsis-Mortari; Mark J Osborn; Colby J Feser; Govindarajan Thangavelu; Wolfgang Melchinger; Yosef Refaeli; Geoffrey R Hill; David H Munn; William J Murphy; Jonathan S Serody; Ivan Maillard; Katharina Kreymborg; Marcel van den Brink; Chen Dong; Shuyu Huang; Xingxing Zang; James P Allison; Robert Zeiser; Bruce R Blazar
Journal:  JCI Insight       Date:  2019-10-03

Review 4.  The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.

Authors:  Alexander Sankin; Deepa Narasimhulu; Peter John; Benjamin Gartrell; Mark Schoenberg; Xingxing Zang
Journal:  Urol Oncol       Date:  2017-05-08       Impact factor: 3.498

5.  Structure and cancer immunotherapy of the B7 family member B7x.

Authors:  Hyungjun Jeon; Vladimir Vigdorovich; Sarah C Garrett-Thomson; Murali Janakiram; Udupi A Ramagopal; Yael M Abadi; Jun Sik Lee; Lisa Scandiuzzi; Kim C Ohaegbulam; Jordan M Chinai; Ruihua Zhao; Yu Yao; Ying Mao; Joseph A Sparano; Steven C Almo; Xingxing Zang
Journal:  Cell Rep       Date:  2014-10-30       Impact factor: 9.423

Review 6.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Authors:  Ruihua Zhao; Jordan M Chinai; Susan Buhl; Lisa Scandiuzzi; Anjana Ray; Hyungjun Jeon; Kim C Ohaegbulam; Kaya Ghosh; Aimin Zhao; Matthew D Scharff; Xingxing Zang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

8.  Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes.

Authors:  Ilian A Radichev; Lilia V Maneva-Radicheva; Christina Amatya; Maryam Salehi; Camille Parker; Jacob Ellefson; Paul Burn; Alexei Y Savinov
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

Review 9.  Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

Authors:  Amer Assal; Justin Kaner; Gopichand Pendurti; Xingxing Zang
Journal:  Immunotherapy       Date:  2015-11-16       Impact factor: 4.196

10.  B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis.

Authors:  R D Pawar; B Goilav; Y Xia; L Herlitz; J Doerner; S Chalmers; K Ghosh; X Zang; C Putterman
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.